drugset / Trial / NCT00141661

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

NCT00141661

Phase 2 Completed 67 enrolled Pfizer Trans Tech Pharmaceuticals · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.

Timeline

Start
2005-10
Primary completion
2006-06
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Azeliragon Small molecule 10 mg Oral
Subject Azeliragon Small molecule 20 mg Oral

Indications